Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Sclerosis and Related Disorders Channel:
NMOSD

Welcome to The NMOSD Channel

VJNeurology brings you the latest updates in neuromyelitis optica spectrum disorder (NMOSD) directly from world-leading experts. The NMOSD Channel brings you video interviews from international conferences.

Discover key developments in this space, including updates in disease biology, novel treatment strategies, and ongoing clinical trials.

Recent evidence for subclinical disease activity in NMOSD 6:38
Recent evidence for subclinical disease activity in NMOSD
Bruce Cree • 21 Oct 2021
Novel treatment strategies for NMOSD 1:21
Novel treatment strategies for NMOSD
Kazuo Fujihara • 4 Oct 2021
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD 5:10
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD
Kazuo Fujihara • 4 Oct 2021
Symptomatic treatment of NMOSD 2:24
Symptomatic treatment of NMOSD
Kazuo Fujihara • 4 Oct 2021
Diagnostic criteria and treatment updates for NMOSD 5:44
Diagnostic criteria and treatment updates for NMOSD
Kazuo Fujihara • 4 Oct 2021
Prognostic factors in NMOSD: age, ethnicity, and relapse history 2:07
Prognostic factors in NMOSD: age, ethnicity, and relapse history
Dalia Rotstein • 8 Oct 2021
Key research questions in seronegative NMOSD 1:30
Key research questions in seronegative NMOSD
Dalia Rotstein • 8 Oct 2021
Identifying risk factors for AQP4+ NMOSD 3:18
Identifying risk factors for AQP4+ NMOSD
Dalia Rotstein • 8 Oct 2021
Retinal atrophy independent of optic neuritis in AQP4+ NMOSD 6:47
Retinal atrophy independent of optic neuritis in AQP4+ NMOSD
Elias Sotirchos • 18 Oct 2021
Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD 3:11
Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD
Celia Oreja-Guevara • 14 Oct 2021
Current and emerging therapeutics for NMOSD 1:28
Current and emerging therapeutics for NMOSD
Nikolaos Grigoriadis • 20 Sep 2021
Relapses and progression in NMOSD and MS: understanding the underlying mechanisms 2:59
Relapses and progression in NMOSD and MS: understanding the underlying mechanisms
Nikolaos Grigoriadis • 20 Sep 2021
Is AQP4-IgG NMOSD an exclusively relapsing disease? 3:38
Is AQP4-IgG NMOSD an exclusively relapsing disease?
Nikolaos Grigoriadis • 20 Sep 2021
Differentiating NMOSD and MS 2:05
Differentiating NMOSD and MS
Nikolaos Grigoriadis • 8 Jun 2021
Predictive and prognostic biomarkers for pediatric MOGAD and NMOSD 3:04
Predictive and prognostic biomarkers for pediatric MOGAD and NMOSD
Brenda Banwell • 26 Apr 2021
Update on pediatric NMOSD and MOGAD 3:47
Update on pediatric NMOSD and MOGAD
Brenda Banwell • 26 Apr 2021
The content of VJNeurology is intended for healthcare professionals